Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    20

Stocks News & Analysis

stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks

Nvidia: Back in business in China; Raising fair value estimate

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,816.4058.90-0.66%
CAC 407,774.858.640.11%
DAX 4024,200.10139.810.58%
Dow JONES (US)44,023.29436.36-0.98%
FTSE 1008,971.0332.710.37%
HKSE24,517.7672.36-0.29%
NASDAQ20,677.8037.470.18%
Nikkei 22539,663.4014.62-0.04%
NZX 50 Index12,754.5964.960.51%
S&P 5006,243.760.000.00%
S&P/ASX 2008,561.8068.50-0.79%
SSE Composite Index3,503.781.22-0.03%

Market Movers